|
業務類別
|
Biotechnology |
|
業務概覽
|
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226. |
| 公司地址
| 221 Crescent Street, Building 23, Suite 105, Waltham, MA, USA, 02109 |
| 電話號碼
| +1 781 281-9020 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.damoratx.com |
| 員工數量
| 7 |
| Mr. Sherwin Sattarzadeh |
Chief Operating Officer |
-- |
23/03/2026 |
| Ms. Lori Firmani |
Chief Financial Officer and Principal Accounting Officer |
美元 311.25K |
29/04/2026 |
| Mr. Garrett Winslow |
General Counsel and Corporate Secretary |
美元 400.40K |
29/04/2026 |
| Ms. Jennifer Ann Jarrett |
Director, President and Chief Executive Officer |
-- |
23/03/2026 |
| Dr. Becker Hewes, M.D. |
Chief Medical Officer |
-- |
29/04/2026 |
|
|
| Mr. Peter Harwin |
Chairman of the Board |
23/03/2026 |
| Ms. Julianne Bruno |
Independent Director |
29/04/2026 |
| Dr. Christopher Cain, PhD |
Independent Director |
29/04/2026 |
| Dr. Cameron Turtle, D.Phil. |
Director |
23/03/2026 |
| Ms. Jennifer Ann Jarrett |
Director, President and Chief Executive Officer |
23/03/2026 |
| Mr. Michael Landsittel, M.B.A. |
Director |
23/03/2026 |
|
|
|
|
